Wuhan RS Pharmaceuticals Co., Ltd. was founded in April 2009, located in Gedian Economic and Technological Development Zone, Ezhou City, Hubei Province, is a modernized generic drug research and development and API production enterprise in line with FDA and cGMP, with an investment of RMB 300 million in the first phase, covering an area of 172 acres, and 200 acres in the second phase, totaling 372 acres. The first phase construction was completed at the end of December 2012, and the trial production started in April 2013. In October 2013, we obtained the drug production license of Wuhan Ruisheng Pharmaceutical Co., Ltd. and the 2010 GMP certificates of Atorvastatin Calcium and Fasudil Mesylate. The first phase of the construction includes a pilot plant for pharmaceutical raw materials, a multi-functional plant, a vertical flow synthesis plant, a hydrogenation plant and its supporting utility works, such as boiler room, engineering building and sewage treatment station. The company currently employs more than 130 people, and the number of employees is expected to exceed 300 after the completion of Phase II construction.
No. of employees